CRBU News and Press, Caribou Biosciences Inc. From 11/07/23

2023-11-07 17:23:40 ET More on Caribou Bioscience Caribou Biosciences: Antlers Up, Bullish Run In Phase 1 Trials Caribou Biosciences, Inc. 2023 Q2 - Results - Earnings Call Presentation AbbVie ends Caribou agreement on CAR-T therapy development Seeking Alpha&...

-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment ongoing in r/r MM patients -- -- CB-0...

-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appoin...

-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the clinic -- BERKELEY, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, ...

2023-10-11 06:00:00 ET You don't have to invest a pile of cash to get in on some of biotech's exciting players early in their growth story. In fact, with just a few dollars, you can pick up shares of a company that could eventually make a big mark in the world of healthcare. Of course, ...

2023-10-10 05:40:00 ET Just when it seemed like the market was on its way to new heights, 2023 showed us it wasn't done flinging uncertainty at our expectations. This summer, the benchmark S&P 500 index climbed to within a few percentage points of its all-time high, only to tank aga...

2023-09-28 17:35:11 ET More on AbbVie, Caribou Bioscience, etc. Caribou Biosciences: Antlers Up, Bullish Run In Phase 1 Trials AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis) AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemot...

2023-09-27 08:30:00 ET Despite a sizzling start to the year, growth stocks have suddenly found themselves on the outs with investors. Concerns about the global economy, persistently high interest rates, and stubborn levels of inflation have weighed heavily on pure-play growth stocks in the ...

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki bring...

2023-09-23 08:45:00 ET In our modern age, the power of gene editing is undeniable. After years of foundational scientific research, it's now becoming possible to treat illnesses that were until very recently intractable. And (as is usually the case during periods of great innovation), there...